|
 |
| home > epc > autumn 2002 > a different strategy in a changing world of infectious substances |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
On the 5th July 2002 UN scrutinisers voted unanimously passing far-reaching legislation for the next edition (13th revised edition) on infectious substances. It is quite remarkable, considering that only a year ago it would have taken a days spirited debate just to change a few words in the existing text. Was there a momentous sea-change by experts on their views of dangerous bugs? Or did other influences come to bear? Think back to the autumn of 2001.
The deliberate release of biological agents through the mail system in the United States completely changed the focus on hazardous materials. 'Hazmat' bioterror swiftly shot up the political and scientific agenda. Many governments, particularly in North America and Europe, took measures to increase preparedness and response capacity. Therefore, not surprisingly, transport officials needed to open a dialogue with the scientific community and start to understand the rationales which underpin the infectious substance class. This UN meeting was the culmination of a year's solid work for regulators and scientists. Many observers agree that the impending '13th revised edition' is unequivocally a positive regulatory milestone. Now it remains to be seen how the world will progress in the intervening years until it is published in 2004.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Global Clinical Outsourcing Partnerships
26-27 March 2009, Mariott Hotel, Brussels
This Jacob Fleming event is designed to promote direct business. It features a two-day educational session with case studies, presentations and interactive sessions. This forum offers networking and the forging of new business partnerships in a unique business-driven environment.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
